Dermatomyositis is a rare systemic autoimmune disease characterized by chronic inflammation, progressive muscle weakness, and prominent cutaneous manifestations, with limited approved treatment options. Brepocitinib (Lisraya ® ), an orally administered dual tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1) inhibitor, received the U.S. Food and Drug Administration approval on August 27, 2026, for the treatment of dermatomyositis in adults. Unlike broader JAK inhibitors, brepocitinib exhibits preferential activity against JAK1 and TYK2 over JAK2 and JAK3, providing a differentiated kinase-selectivity profile. In the phase 3 VALOR trial, once-daily brepocitinib 30 mg significantly improved the Total Improvement Score and multiple measures of dermatomyositis disease activity compared with placebo. Its approval highlights the successful application of kinase-directed medicinal chemistry to a rare autoimmune disease and provides a new oral therapeutic option for adults with dermatomyositis.
Brepocitinib (Lisraya ® ), a first orally administered small molecule dual TYK2/JAK1 inhibitor approved for dermatomyositis in adults. // Neuroretina. – 2026. – DOI: 10.1007/s00044-026-03637-z. – URL: https://link.springer.com/article/10.1007/s00044-026-03637-z
(2026). Brepocitinib (Lisraya ® ), a first orally administered small molecule dual TYK2/JAK1 inhibitor approved for dermatomyositis in adults. Neuroretina. https://doi.org/10.1007/s00044-026-03637-z
“Brepocitinib (Lisraya ® ), a first orally administered small molecule dual TYK2/JAK1 inhibitor approved for dermatomyositis in adults.” Neuroretina, 2026. doi:10.1007/s00044-026-03637-z.
@article{article34989,
title = {Brepocitinib (Lisraya ® ), a first orally administered small molecule dual TYK2/JAK1 inhibitor approved for dermatomyositis in adults},
journal = {Neuroretina},
year = {2026},
doi = {10.1007/s00044-026-03637-z},
url = {https://link.springer.com/article/10.1007/s00044-026-03637-z}
}
Purpose The engineered v5.9 DNA polymerase has been reported to exhibit enhanced thermostability in loop-mediated isothermal amplification (LAMP). As an initial step toward field-deployable molecular diagnosis of giardiasis, we...
Background Polygenic risk scores for cardiovascular disease show poor agreement between methods, and most treat sex as a covariate rather than stratifying by it, despite well-documented sex differences in disease incidence and outcomes....
Communications Medicine, Published online: 19 November 2026; doi:10.1038/s43856-026-02013-7 The authors identify the mitochondrial RNA methyltransferase, NSUN4 as a potential therapeutic target in intrahepatic cholangiocarcinoma, with...
Communications Medicine, Published online: 19 November 2026; doi:10.1038/s43856-026-02009-3 People with type 2 diabetes can have too much sugar in their blood stream, which can lead to health problems. Metformin is a common medication...
Cognitive tests are commonly used to evaluate the effects of cognitive and exercise interventions in Parkinson’s disease, but their ability to distinguish genuine change from measurement variability remains insufficiently characterized....